Hypertension At Bristol Myers
To Wall Street, it looked like a sure bet. A Food & Drug Administration panel was set to meet on May 1 to decide whether to recommend approval of Bristol-Myers Squibb Co.'s new super-powerful hypertension drug Vanlev. The FDA had already granted the drug an accelerated review, giving investors confidence that it would get the agency's O.K. and be on the market later this year. And analysts such as SG Cowen Securities Corp.'s Stephen M. Scala were expecting Vanlev to be a blockbuster, racking up sales of $2 billion by 2003.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Uber Paid Hackers to Delete Stolen Data on 57 Million People
- Tesla’s Burning Through Nearly Half a Million Dollars Every Hour
- New Uber CEO Keeps Finding Horrors at Every Turn
- Facebook to Show Users Which Russian Propaganda They Followed
- Jamie Dimon Says He'd Bet Donald Trump Doesn't Win Again in 2020